[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphoproliferative-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphoproliferative-disease":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,38,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100632874","a-comprehensive-register-of-lymphoproliferative-disorders-rely-100632874",false,"NCT07519356","A Comprehensive Register Of Lymphoproliferative Disorders (ReLy)","Inclusion Criteria:\n\n* Patients ≥ 18 years diagnosed with and\u002For treated for lymphoproliferative disorders.\n* Prospective patients (or their or legal guardians) who have the ability to understand and be willing to sign a written informed consent document\n* Retrospective patients who have signed the institutional document allowing the use of their data for research on their disease\n\nExclusion Criteria:\n\n* Patients who are unable to understand informed consent document","ALL","18 Years",{"count":18,"type":19},9000,"ESTIMATED","10 Years","OBSERVATIONAL","The primary objective of this study is to assess the 10-year overall survival (OS) of patients with different lymphoproliferative disorders. Secondary objectives include evaluating the comorbidities and fitness of patients and their impact on treatment choices and outcomes. Additionally, the study will examine the effectiveness of various therapeutic regimens, with a particular focus on new treatments, such as chemo-free protocols, targeted drugs, and cell therapies, in order to determine the best treatment sequence for refractory and relapsed cases.\n\nThe research will also investigate how clinical and biological factors influence disease progression or relapse. Another aim is to explore potential correlations between genotype, clinical phenotype, and outcomes, both at diagnosis and during various disease stages. The study will also assess the incidence of tumor lysis syndrome and other adverse events during treatment, considering how these factors might affect treatment discontinuations or dose reductions.\n\nAnother objective is to evaluate the outcomes of patients who are managed with a \"watch and wait\" approach. Long-term toxicities and the occurrence of secondary malignancies will also be studied, alongside the analysis of healthcare costs and the resources used in patient management.",[24],"Lymphoproliferative Disease","RECRUITING","2026-04-02",{"date":28,"type":29},"2026-04-09","ACTUAL",{"date":31,"type":29},"2022-06-09",{"date":33,"type":19},"2030-12-30",{"name":35,"class":36},"Fondazione IRCCS Policlinico San Matteo di Pavia","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":5},"100175292","phase-1-cytotoxic-t-lymphocytes-for-ebv-positive-lymphoma-grale-100175292","NCT01555892","Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE","Administration of Rapidly Generated EBV-Specific Cytotoxic T-Lymphocytes To Patients With EBV-Positive Lymphoma","GRALE","Inclusion Criteria at time of Procurement\n\n1. Any patient, regardless of age or sex, with EBV-positive Hodgkin's or non-Hodgkin's Lymphoma, (regardless of the histological subtype) or EBV (associated)-T\u002FNK-lymphoproliferative disease or Severe Chronic Active EBV (CAEBV) who may subsequently be eligible for the treatment component\n2. EBV positive tumor (can be pending at this time)\n3. Weighs at least 12kg\n4. Informed consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent.\n\nInclusion Criteria at time of Infusion\n\n1. Any patient, regardless of age or sex, with EBV-positive Hodgkin's or non-Hodgkin's Lymphoma (regardless of histologic subtype), or EBV (associated)-T\u002FNK-lymphoproliferative disease or Severe Chronic Active EBV (CAEBV)\\* and\n\n   In second or subsequent relapse (or first relapse or with active disease if immunosuppressive chemotherapy contraindicated or multiply relapsed patients in remission who have a high risk of relapse)\\*\\* OR any patient with primary disease or in first remission if immunosuppressive chemotherapy is contraindicated, e.g. patients who develop Hodgkin disease after solid organ transplantation or if the Lymphoma is a second malignancy e.g. a Richter's transformation of CLL. (Group A)\n\n   OR\n\n   In remission or with minimal residual disease status after autologous or syngeneic SCT. (Group B)\n2. EBV positive tumor\n3. Patients with bilirubin less than or equal to 3x upper limit of normal, AST less than or equal 5x upper limit of normal, and hemoglobin greater than or equal to 7.0 (may be a transfused value).\n4. Patients with a creatinine less than or equal to 2x upper limit of normal for age\n5. Pulse oximetry of \\> 90% on room air\n6. Patients should have been off other investigational therapy for 4 weeks prior to entry in this study. PD1\u002FPDL inhibitors will be allowed if medically indicated.\n7. Patients with a Karnofsky\u002FLansky score of greater than or equal to 50\n8. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded.\n9. Informed consent explained to, understood and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent.\n\n   * CAEBV is defined as patients with high EBV viral load in plasma or PBMC (\\> 4000 genomes per ug PBMC DNA) and\u002For biopsy tissue positive for EBV\n\n     * Patients with relapsed or refractory lymphoma that are eligible for a stem cell transplant will not be treated on this study as an alternative to transplant.\n\nExclusion Criteria at Time of Procurement\n\n1\\. Active infection with HIV, HTLV, HBV, HCV (can be pending at this time)\n\nExclusion Criteria at Time of Infusion\n\n1. Pregnant or lactating\n2. Severe intercurrent infection.\n3. Current use of systemic corticosteroids \\> 0.5 mg\u002Fkg\u002Fday",{"count":47,"type":19},136,"INTERVENTIONAL",[50],"PHASE1","Subjects have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T\u002FNK-lymphoproliferative disease or severe chronic active Epstein Barr Virus (CAEBV) which has come back, is at risk of coming back, or has not gone away after treatment, including the best treatment investigators know for these diseases.\n\nSome of these patients show signs of virus that is called Epstein Barr virus (EBV) that causes mononucleosis or glandular fever (\"mono\" or the \"kissing disease\") before or at the time of their diagnosis. EBV is found in the cancer cells of up to half the patients with HD and NHL, suggesting that it may play a role in causing Lymphoma. The cancer cells and some immune system cells infected by EBV are able to hide from the body's immune system and escape destruction. Investigators want to see if special white blood cells, called GRALE T cells, that have been trained to kill EBV infected cells can survive in the blood and affect the tumor.\n\nInvestigators have used this sort of therapy to treat a different type of cancer called post transplant lymphoma. In this type of cancer the tumor cells have 9 proteins made by EBV on their surface. Investigators grew T cells in the lab that recognized all 9 proteins and were able to successfully prevent and treat post transplant lymphoma. However, in HD and NHL, T\u002FNK-lymphoproliferative disease, and CAEBV, the tumor cells and B cells only express 4 EBV proteins. In a previous study, the investigators made T cells that recognized all 9 proteins and gave them to patients with HD. Some patients had a partial response to this therapy but no patients had a complete response. The investigators then did follow up studies where investigators made T cells that recognized the 2 EBV proteins seen in patients with lymphoma, T\u002FNK-lymphoproliferative disease and CAEBV. Investigators have treated over 50 people on those studies. About 60% of those patients who had disease at the time they got the cells had responses including some patients with complete responses. This study will expand on those results and the investigators will try and make the T cells in the lab in a simpler faster way. These cells are called GRALE T cells. These GRALE T cells are an investigational product not approved by the FDA.\n\nThe purpose of this study is to find the largest safe dose of LMP-specific cytotoxic GRALE T cells created using this new manufacturing technique. Investigators will learn what the side effects are and to see whether this therapy might help patients with HD or NHL or EBV associated T\u002FNK-lymphoproliferative disease or CAEBV.",[53,54,24,55],"Hodgkin's Disease","Non-Hodgkin's Lymphoma","Lymphoma",[57,58,54,59,60,61,62,63,64],"EBV","Hodgkin's Lymphoma","Lymphoma Relapse","Autologous or Syngeneic Stem Cell Transplant","T\u002FNK-lymphoproliferative disease","LMP","BARF1","EBNA1","2026-02-26",{"date":67,"type":29},"2026-03-02",{"date":69,"type":29},"2013-01-14",{"date":71,"type":19},"2027-07-01",{"name":73,"class":36},"Baylor College of Medicine",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":48,"phases":83,"briefSummary":85,"conditions":86,"keywords":91,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":106,"leadSponsor":108,"locationsCount":37},"100565604","remote-multichannel-monitoring-of-patients-with-chronic-diseases-using-speech-technologies-based-on-artificial-intelligence-100565604","NCT06644339","Remote Multichannel Monitoring of Patients With Chronic DIseAses Using Speech technoLogies Based On Artificial intelliGence","DIALOG","Inclusion Criteria:\n\n* Disease diagnosed according to the latest Clinical practice guidelines\n* Stable condition at the time of discharge from the hospital\n* Written informed consent to participate in the study\n\nNon-inclusion criteria:\n\n* Diagnosed dementia or severe cognitive impairment\n* The inability to use automatic devices to register blood pressure at home, a blood glucose meter\n* Alcohol or drug abuse\n* Inability to contact a voice assistant and other study requirements, due to major co-morbidities, social or financial issues, or a history of noncompliance with medical regimens, that might compromise the patient's ability to understand and\u002For comply with the protocol instructions or follow-up procedures\n\nExclusion Criteria:\n\n* Unwillingness of the patient to continue participating in the study\n* The development of conditions related to the criteria of non-inclusion",{"count":82,"type":19},500,[84],"NA","DIALOG is a study to assess the efficacy and safety of remote patient monitoring using virtual operator voice technologies and a business intelligence (BI) system for timely detection, prevention of early complications, worsening of the condition, and other adverse events in patients who have been discharged from the hospital.",[87,88,89,24,90],"Heart Failure","Diabetes Mellitus","Arterial Hypertension","Total Knee Replacement",[92,93,94,95,96,97,98,99,100],"heart failure","diabetes mellitus","arterial hypertension","lymphoproliferative diseases","knee replacement","remote monitoring","mHealth","telemedicine","voice assistant","NOT_YET_RECRUITING","2024-10-15",{"date":104,"type":29},"2024-10-16",{"date":102,"type":19},{"date":107,"type":19},"2025-04-30",{"name":109,"class":36},"I.M. Sechenov First Moscow State Medical University"]